Applied Therapeutics Shares Surge as Legal Settlement Fuels Investor Confidence

Shares of Applied Therapeutics experienced a dramatic upswing on Tuesday, posting an impressive gain of over 11%. The stock reached $1.13, continuing a substantial rally that has been building momentum over recent weeks.

Technical Momentum Builds

From a technical perspective, the current price movement is remarkable. The equity has surged nearly 90% within a single week and has advanced more than 150% over the past month. Trading well above its 50-day moving average, the stock demonstrates clear bullish sentiment in the short term. However, questions remain about whether this momentum-driven enthusiasm can be sustained, particularly given the biotechnology sector’s notorious volatility.

Resolving Legal Challenges

The recent optimism stems from the company’s settlement agreement in an investor lawsuit. This legal action was originally filed following the FDA’s rejection of Applied Therapeutics’ lead drug candidate, Govorestat, late in 2024. The U.S. regulatory agency had cited “deficiencies in clinical application” at that time, triggering an 80% collapse in the company’s share price.

Should investors sell immediately? Or is it worth buying Applied Therapeutics?

The lawsuit contained serious allegations, claiming the company had misrepresented the strength of clinical trial data, downplayed regulatory risks, and exaggerated the drug’s approval prospects. By reaching this settlement, Applied Therapeutics aims to put this legal burden behind it.

Future Prospects and Challenges

Market attention now turns to the upcoming quarterly results scheduled for November 5 or 6, 2025. More significantly, the company intends to resubmit Govorestat for regulatory approval—this time targeting SORD deficiency, a rare genetic disease. The application is expected to reach the FDA after the first quarter of 2025.

While numerous market analysts maintain “buy” recommendations on the stock, the critical question remains whether Applied Therapeutics can successfully navigate regulatory requirements this time and permanently restore investor trust. The company must demonstrate it has learned from previous setbacks to capitalize on its current positive trajectory.